About Panbio Medical Innovations
Since 2001, Panbio Medical has focused on the development, manufacture and marketing of advanced consumer and professional medical diagnostic products. Through strategic acquisitions and the effective use of a vast intellectual property portfolio, the company now operates on a global scale providing locally relevant, world-class diagnostic tests and services to customers in the private, public and non-government organisational (NGO) sectors.
Inverness Medical concentrates its efforts in five key areas: infectious diseases, cardiology, women’s health, drugs of abuse and oncology. The organisation owns numerous patented technologies for both consumer and professional diagnostics, and offers an expanding range of products that includes brands such as Clearview, Testpack, Binax, Determine, and Biosite.
Inverness Medical is led by an experienced and committed executive team dedicated to bringing to market new and innovative products through breakthrough research and development. Strategic acquisitions are particularly meaningful to the business, enabling it to expand and diversify its range of offerings.
Through acquisitions Inverness Medical has become one of the largest patient health management providers in the world. We enable and empower patients and their families to take charge of their own health.
In January 2008, Inverness Medical acquired Panbio Limited − a leading developer of tests used in the diagnosis of flaviviruses and other arthropod-borne viruses. Panbio was first-to-market with diagnostics for Ross River virus, West Nile virus, Japanese Encephalitis and dengue fever and its range of technical platforms includes enzyme-linked immmunosorbant assay (ELISA) and rapid lateral flow technology. Panbio® now lives on as a premium Australian brand of diagnostic products within the global Inverness medical portfolio. The Panbio® range of dengue diagnostics leads the world in dengue detection.
Today, Inverness medical is the world’s sixth largest, and fastest growing, global in vitro diagnostics company. The organisation has major research and development and manufacturing facilities in North America, Europe, the Middle East and Asia Pacific and global sales and distribution capabilities are also undergoing rapid expansion.
With its global footprint and time-tested brands Inverness Medical continues to maintain focus on locally relevant disease areas ensuring that our customers have the tools for the diagnosis and management of diseases and conditions.
Please note these products are not for sale or distribution in the United States and may not be available in all countries worldwide. Please contact Inverness Medical or your local Panbio distributor to determine availability.
The Panbio Dengue Early ELISA is a dengue NS1 antigen capture ELISA. It is for the qualitative detection of NS1 antigen (serotypes 1, 2, 3 and 4) in serum and used as an aid in the clinical laboratory diagnosis of patients with clinical symptoms consistent with dengue fever.
The Panbio Dengue IgM Capture ELISA is for the qualitative detection of IgM antibodies to dengue antigen in serum, as an aid in the clinical laboratory diagnosis of patients with clinical symptoms consistent with dengue fever.
The Panbio Dengue IgG Capture ELISA is for the qualitative detection of elevated IgG antibodies to dengue virus (serotypes 1, 2, 3 and 4) in serum. This test is intended as an aid in the clinical laboratory diagnosis of secondary dengue virus infection, and can be used in conjunction with the Panbio Dengue IgM Capture ELISA for the presumptive differentiation between primary and secondary infection.
The Panbio Dengue Duo IgM Capture & IgG Capture ELISA is for the qualitative detection of IgM and IgG antibodies to dengue virus in serum.
The Panbio Dengue IgG Indirect ELISA is for the qualitative detection of IgG antibodies to dengue antigen in serum, as an aid in the clinical laboratory diagnosis of patients with clinical symptoms and past exposure consistent with dengue fever.
The Panbio Dengue Duo Cassette is a rapid immunochromatography test designed for the qualitative presumptive detection of IgM and IgG antibodies to dengue virus in human serum, plasma and whole blood.
Tony Fred, CEO
Founder and chief visionary, Tony is the driving force behind the company. He loves to keep his hands full by participating in the development of the software, marketing, and customer experience strategies.
Mich Stark, COO
Mich loves taking on challenges. With his multi-year experience as Commercial Director in the software industry, Mich has helped the company to get where it is today. Mich is among the best minds.
Aline Turner, CTO
Aline is one of the iconic people in life who can say they love what they do. She mentors 100+ in-house developers and looks after the community of thousands of developers.
Iris Joe, CFO
Iris, with her international experience, helps us easily understand the numbers and improves them. She is determined to drive success and delivers her professional acumen to bring the company to the next level.